Intellia Therapeutics Q2 2024 GAAP EPS $(1.52) Misses $(1.24) Estimate, Sales $6.957M Miss $19.162M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics reported a Q2 2024 GAAP EPS of $(1.52), missing the estimate of $(1.24). Sales were $6.957 million, significantly below the $19.162 million estimate.
August 08, 2024 | 11:37 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Intellia Therapeutics reported disappointing Q2 2024 results with a GAAP EPS of $(1.52) missing the $(1.24) estimate and sales of $6.957 million missing the $19.162 million estimate.
The significant miss on both EPS and sales estimates is likely to negatively impact NTLA's stock price in the short term as it indicates weaker-than-expected financial performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100